A glyco-engineered antibody from French firm GamaMabs Pharma SA has demonstrated longer than expected progression-free survival rates in patients with metastatic colorectal cancer also treated with trifluridine/tipiracil (FTD/TPI – Lonsurf). The improvement was especially marked in patients with medium to high expression of anti-Müllerian hormone receptor II (AMHRII), which the antibody, murlentamab, is designed to target.
The Phase II results presented at the European Society of Medical Oncology World Congress on Gastrointestinal Cancer in Barcelona, Spain,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?